DAYTON CLINICAL ONCOLOGY PROGRAM

代顿社区临床肿瘤学项目（DCOP）提供以下途径： 国家合作临床试验，11个国家超过150万人 俄亥俄州西南部的县。 在这一背景下，我们制定了 一个由九家医院组成的联盟，负责进行社区临床试验。 联盟中的9个登记处报告了5，000多名新癌症患者 自1980年以来，每年增长超过100%。 DCOP汇集了一组的力量和资源， 多学科研究者合作开展研究 来自SWOG、NSABP和MDACC。 调查人员49人，其中22人 血液学家/肿瘤学家和27名外科，泌尿科， 病理学和放射治疗。 在未来五年，总体目标是降低癌症发病率， 发病率和死亡率，加速新开发的 癌症预防，早期发现，治疗，病人管理， 康复和持续护理技术，以广泛的社区 应用程序. 通过精心设计，该计划将集中超过50%的我们 关注癌症控制研究并提供资源。 这些互补 治疗和癌症控制的目标是一个现成的匹配， 患者人群，并符合DCOP的兴趣和能力。 DCOP的近期目标是继续保持我们强劲的应计率， 治疗试验;促进更广泛的社区参与，包括 少数群体和得不到充分服务的人口在治疗和癌症方面的作用 NCI批准的对照研究;使用专业教育研讨会 作为技术转让的工具;培养与初级保健的联系 可能有助于癌症控制的医生和其他专家 并继续完善癌症控制数据管理 能力，包括使用一系列资源， 癌症控制研究项目的潜在候选人。 的 乳腺癌预防试验（BCPT）和前列腺 癌症预防试验（PCPT）是主要目标。我们期望赚取 到2000年将超过1500个学分。 总而言之，DCOP跟踪记录证明了管理 复杂的临床研究和癌症控制活动， 最高质量的数据。 DCOP拥有设施和训练有素的 专业人员支持癌症治疗和癌症控制 审判 DCOP人员配置模式、礼宾管理程序， 患者/参与者管理方法，质量控制机制， 药房控制机制、IRB结构和联络均已到位 并发挥作用，以支持当前和未来的治疗和癌症 控制活动。

The Dayton Community Clinical Oncology Program (DCOP) provides access to national cooperative clinical trials for over 1.5 million people in 11 counties in southwestern Ohio. Against this background, we have developed a nine-hospital consortium for the conduct of community clinical trials. The 9 registries in the consortium report over 5,000 new cancer patients per year, an increase of over 100% since 1980. The DCOP brings together the strength and resources of a group of multidisciplinary investigators who collaborate in the conduct of studies from SWOG, NSABP, and MDACC. The investigators number 49 including 22 hematologists/oncologists and 27 colleagues in surgery, urology, pathology, and radiation therapy. Over the next five years, the overall aim is to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management, rehabilitation, and continuing care technology to widespread community application. By careful design, the program will focus over 50% of our attention and resources on cancer control research. These complementary objectives of both treatment and cancer control are a ready match for the patient population and fit within DCOP interests and capabilities. The immediate goals of the DCOP are to continue our strong accrual rate to treatment trials; to facilitate wider community participation, including minority groups and underserved populations in treatment and cancer control research approved by NCI; to use professional education symposia as a tool for technology transfer; to cultivate contacts with primary care physicians and other specialists who may contribute to cancer control initiatives; and to continue to refine cancer control data management capabilities, including the use of a range of resources to identify potential candidates for cancer control research projects. The continuation of the Breast Cancer Prevention Trial (BCPT) and the Prostate Cancer Prevention Trial (PCPT) are primary objectives. We expect to earn over 1500 credits by the Year 2000. In summary, the DCOP track record demonstrates the ability to manage complex clinical research and cancer control activities while producing the highest quality data. The DCOP has the facilities and well-trained professional personnel to support both cancer treatment and cancer control trials. The DCOP staffing pattern, protocol management procedures, patient / participant management approaches, quality control mechanisms, pharmacy control mechanisms, IRB structure and liaison are all in place and functioning to support current and future therapeutic and cancer control activities.